Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
$1.36
+3.0%
$1.30
$1.05
$10.16
$42.79M1.65413,651 shs225,904 shs
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
$8.36
+9.0%
$7.06
$5.47
$11.99
$173.47MN/A67,524 shs58,818 shs
Cybin Inc. stock logo
CYBN
Cybin
$7.15
+3.3%
$7.70
$4.81
$13.88
$168.67M0.68320,399 shs592,066 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$13.08
+4.1%
$13.01
$7.09
$27.38
$164.65M0.45194,949 shs124,264 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
+1.54%-5.04%-5.04%+12.82%-85.64%
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
-0.26%-6.81%+22.36%-25.85%-10.93%
Cybin Inc. stock logo
CYBN
Cybin
+4.85%-3.49%-10.48%-7.36%+1,775.34%
Lifevantage Corporation stock logo
LFVN
Lifevantage
+1.37%-8.11%-3.08%-0.71%+48.41%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
2.7444 of 5 stars
3.53.00.00.01.52.50.6
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Cybin Inc. stock logo
CYBN
Cybin
2.4521 of 5 stars
3.60.00.00.01.70.81.3
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.934 of 5 stars
3.50.01.72.71.42.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
3.00
Buy$17.571,192.02% Upside
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
3.00
Buy$20.50145.22% Upside
Cybin Inc. stock logo
CYBN
Cybin
3.25
Buy$85.001,088.81% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.00
Buy$30.50133.18% Upside

Current Analyst Ratings Breakdown

Latest ACRV, LFVN, CYBN, and ACTU Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/18/2025
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
8/14/2025
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$9.00 ➝ $8.00
7/8/2025
Cybin Inc. stock logo
CYBN
Cybin
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$73.00 ➝ $70.00
6/3/2025
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy$20.00
(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
N/AN/AN/AN/A$4.55 per shareN/A
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
N/AN/AN/AN/A($0.13) per shareN/A
Cybin Inc. stock logo
CYBN
Cybin
N/AN/AN/AN/A$10.83 per shareN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$222.35M0.74$0.93 per share14.06$2.05 per share6.38
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
-$80.56M-$2.25N/AN/AN/AN/A-50.78%-46.08%N/A
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
-$27.28MN/A0.00N/AN/A-19,736.59%-281.83%N/A
Cybin Inc. stock logo
CYBN
Cybin
-$57.88M-$4.60N/AN/AN/AN/A-37.58%-36.59%N/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$2.94M$0.6918.96N/A4.12%34.67%15.24%8/27/2025 (Estimated)

Latest ACRV, LFVN, CYBN, and ACTU Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/27/2025Q4 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.17N/AN/AN/A$57.93 millionN/A
8/14/2025Q2 2025
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
-$0.19-$0.30-$0.11-$0.30N/AN/A
8/13/2025Q2 2025
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
-$0.57-$0.55+$0.02-$0.55N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
N/AN/AN/AN/AN/A
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
N/AN/AN/AN/AN/A
Cybin Inc. stock logo
CYBN
Cybin
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.181.38%N/A26.09%3 Years
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
N/A
10.31
10.31
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
N/A
0.73
0.46
Cybin Inc. stock logo
CYBN
Cybin
N/A
24.24
24.24
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.66
0.98

Institutional Ownership

CompanyInstitutional Ownership
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
71.62%
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
N/A
Cybin Inc. stock logo
CYBN
Cybin
17.94%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%

Insider Ownership

CompanyInsider Ownership
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
11.90%
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
69.34%
Cybin Inc. stock logo
CYBN
Cybin
15.00%
Lifevantage Corporation stock logo
LFVN
Lifevantage
20.65%
CompanyEmployeesShares OutstandingFree FloatOptionable
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
5831.46 million27.71 millionNot Optionable
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
1020.75 million6.36 millionN/A
Cybin Inc. stock logo
CYBN
Cybin
5023.59 million17.96 millionNot Optionable
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.59 million9.99 millionOptionable

Recent News About These Companies

Lifevantage (LFVN) Expected to Announce Earnings on Wednesday
LifeVantage To Open Iceland Market

New MarketBeat Followers Over Time

Media Sentiment Over Time

Acrivon Therapeutics stock logo

Acrivon Therapeutics NASDAQ:ACRV

$1.36 +0.04 (+3.03%)
Closing price 04:00 PM Eastern
Extended Trading
$1.36 0.00 (0.00%)
As of 04:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Actuate Therapeutics stock logo

Actuate Therapeutics NASDAQ:ACTU

$8.36 +0.69 (+9.00%)
Closing price 04:00 PM Eastern
Extended Trading
$8.40 +0.04 (+0.54%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Cybin stock logo

Cybin NYSE:CYBN

$7.15 +0.23 (+3.32%)
Closing price 04:00 PM Eastern
Extended Trading
$7.18 +0.02 (+0.35%)
As of 04:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$13.08 +0.51 (+4.06%)
Closing price 04:00 PM Eastern
Extended Trading
$13.21 +0.13 (+0.99%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.